Milan, Italy and New York, USA – May 21, 2025 – Altheia Science, a pioneer in the development of transformative cell and gene therapies for autoimmune diseases, proudly announces the success of its strategic collaboration with Anemocyte, a leading developer and manufacturer of pDNA and mRNA headquartered in Italy. This partnership has been instrumental in driving forward Altheia’s therapeutic pipeline, particularly through the timely and effective supply of Master Cell Banks and plasmid DNA for viral vector manufacturing.
“In the rapidly evolving field of advanced therapeutics, speed and precision are crucial, and Anemocyte has proven to be key strategic partner accelerating our path toward clinical trials,” said Paolo Rizzardi, MD, co-founder, Chairman and CEO of Altheia Science. “Their deep expertise, reliability, and unwavering commitment have been critical in ensuring the efficient and timely execution of vital manufacturing steps.”
As Altheia Science pushes the boundaries of science to transform patient care, the collaboration with Anemocyte highlights the importance of robust, agile, and far-sighted manufacturing partnerships. “Altheia Science represents the vanguard of therapeutic innovation, and we are deeply proud to serve as a cornerstone in their manufacturing strategy”, said Marco Ferrari, CEO of Anemocyte. “This collaboration reflects a shared mission to accelerate the delivery of life-changing treatments. At Anemocyte, we are committed to empowering our partners with the tools, knowledge, and capabilities needed to bring breakthrough science to life—swiftly, safely, and at scale.”
About Altheia Science:
Founded by Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with AurorA-TT (www.aurora-tt.com), Altheia Science is a leader in developing pioneering cell and gene therapy strategies to treat autoimmune diseases.
For more information, visit www.altheiascience.com.
About Anemocyte:
Anemocyte is a Biotech Manufacturing Organization (BMO) based in Italy, offering comprehensive development and manufacturing services and providing innovative solutions from R&D to GMP. Specialized in the development and production of pDNA and mRNA, Anemocyte brings over 25 years of expertise in manufacturing innovative therapies and related starting materials.
For more information, visit www.anemocyte.com
Anemocyte Media
Telephone +39 0299372311
Email: media@anemocyte.com
www.anemocyte.com
